0001171843-24-000560.txt : 20240202 0001171843-24-000560.hdr.sgml : 20240202 20240202163032 ACCESSION NUMBER: 0001171843-24-000560 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 19 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeyondSpring Inc. CENTRAL INDEX KEY: 0001677940 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38024 FILM NUMBER: 24591964 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR STREET 2: SUITE 410 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: 646-528-4184 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, WEST SIDE, 4TH FLOOR STREET 2: SUITE 410 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 6-K 1 bysi20230522_6k.htm FORM 6-K bysi20230522_6k.htm
0001677940 BeyondSpring Inc. false --12-31 Q2 2023 0.0001 0.0001 500,000,000 500,000,000 38,999,597 38,999,597 39,015,476 39,015,476 00016779402023-01-012023-06-30 iso4217:USD 00016779402022-12-31 00016779402023-06-30 iso4217:USDxbrli:shares xbrli:shares 00016779402022-01-012022-06-30
 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2024

 

Commission File Number: 001-38024

 

BeyondSpring Inc.

 

BeyondSpring Inc.
100 Campus Drive, West Side, 4th Floor, Suite 410
Florham Park, New Jersey 07932
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

On February 2, 2024, BeyondSpring Inc. (the “Company”) reported financial results for the six months ended June 30, 2023.

 

As previously reported on Form 6-Ks filed by the Company on September 20, 2023 and January 16, 2024, Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), the Company’s 58%-owned subsidiary in China, was party to an arbitration proceeding initiated by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui”). On January 10, 2024, the arbitral tribunal at China International Economic and Trade Arbitration Committee issued a final award, denying all claims made by Hengrui.

 

As a result, all of Wanchunbulin’s assets that have been seized and frozen pending a decision by the arbitral tribunal are expected to be returned to Wanchunbulin. Such seized and frozen assets are reflected in the Company’s balance sheet as of June 30, 2023 as “Restricted Cash.”

 

This Report on Form 6-K is incorporated by reference into the Registration Statement on Form F-3, File No. 333-257639, and the Registration Statements on Form S-8, File No. 333-216639 and File No. 333-240082, of the Company.

 

 

 

 

 

 

 

 

 

 

 

BEYONDSPRING INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2022 AND JUNE 30, 2023

 

(Amounts in thousands of U.S. Dollars ($), except for number of shares and per share data)

 

  

December 31, 2022

  

June 30, 2023

 
   $   $ 
       (Unaudited) 

Assets

        

Current assets:

        

Cash and cash equivalents

  34,396   13,492 

Restricted Cash

  -   9,736 

Short-term investments

  2,872   1,902 

Advances to suppliers

  492   444 

Prepaid expenses and other current assets

  763   217 

Total current assets

  38,523   25,791 
         

Noncurrent assets:

        

Property and equipment, net

  1,868   1,800 

Operating lease right-of-use assets

  5,484   4,946 

Other noncurrent assets

  347   341 

Total noncurrent assets

  7,699   7,087 
         

Total assets

  46,222   32,878 
         

Liabilities and equity

        
         

Current liabilities:

        

Accounts payable

  1,081   1,501 

Accrued expenses

  2,470   1,682 

Current portion of operating lease liabilities

  966   784 

Deferred revenue

  1,351   1,751 

Other current liabilities

  1,484   1,104 

Total current liabilities

  7,352   6,822 
         

Noncurrent liabilities:

        

Operating lease liabilities

  3,995   3,687 

Deferred revenue

  34,221   33,529 

Other noncurrent liabilities

  3,661   3,527 

Total noncurrent liabilities

  41,877   40,743 
         

Total liabilities

  49,229   47,565 
         

Commitments and contingencies

          
         

Mezzanine equity

        

Contingently redeemable noncontrolling interests

  11,074   11,474 
         
Shareholders' deficit        

Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,999,597 and 39,015,476 shares issued and outstanding as of December 31, 2022 and June 30, 2023, respectively)

  4   4 

Additional paid-in capital

  368,857   368,679 

Accumulated deficit

  (375,276)  (387,996)

Accumulated other comprehensive income

  436   1,223 
         

Total BeyondSpring Inc.’s shareholders’ deficit

  (5,979)  (18,090)

Noncontrolling interests

  (8,102)  (8,071)
Total shareholders' deficit  (14,081)  (26,161)
         

Total liabilities, mezzanine equity and shareholders' deficit

  46,222   32,878 

 

 

 

 

BEYONDSPRING INC.

 

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF

 

COMPREHENSIVE LOSS FOR THE SIX MONTHS ENDED JUNE 30, 2022 AND 2023

 

(Amounts in thousands of U.S. Dollars ($), except for number of shares and per share data)

 

  

Six months ended June 30,

 
  

2022

  

2023

 
   $   $ 
         

Revenue

  676   875 
         

Operating expenses

        

Research and development

  (13,992)  (9,214)

General and administrative

  (7,492)  (5,145)
         

Loss from operations

  (20,808)  (13,484)

Foreign exchange loss, net

  (350)  (200)

Interest income

  41   281 

Interest expenses

  (17)  - 

Other income, net

  1,259   133 
         

Loss before income tax

  (19,875)  (13,270)

Income tax expenses (benefits)

  (289)  9 
         

Net loss

  (20,164)  (13,261)

Less: Net loss attributable to noncontrolling interests

  (1,675)  (541)

Net loss attributable to BeyondSpring Inc.

  (18,489)  (12,720)
         

Net loss per share

        

Basic and diluted

  (0.47)  (0.33)
         

Weighted-average shares outstanding

        

Basic and diluted

  39,065,710   38,976,761 
         

Other comprehensive loss, net of tax of nil:

        

Foreign currency translation adjustment

  949   1,249 

Unrealized holding gain (loss)

  30   (5)

Comprehensive loss

  (19,185)  (12,017)

Less: Comprehensive loss attributable to noncontrolling interests

  (1,336)  (84)

Comprehensive loss attributable to BeyondSpring Inc.

  (17,849)  (11,933)
 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

BeyondSpring Inc.

     
     
 

By:

/s/ Lan Huang     
 

Name: Lan Huang

 

Title: Chairperson and Chief Executive Officer

 

Date: February 2, 2024

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.

Exhibit

   

101.INS

Inline XBRL Instance Document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

 

 
EX-101.SCH 2 bysi-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 3 bysi-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 4 bysi-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 bysi-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Notes To Financial Statements Notes To Financial Statements [Abstract] Note To Financial Statement Details Textual us-gaap_IncomeTaxExpenseBenefit Income tax expenses (benefits) Noncurrent liabilities: Equity Components [Axis] Equity Component [Domain] Unrealized holding gain (loss) Other noncurrent assets us-gaap_LiabilitiesCurrent Total current liabilities Other current liabilities us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss before income tax Operating expenses Foreign currency translation adjustment Cash and cash equivalents us-gaap_AssetsCurrent Total current assets Noncurrent assets: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Total shareholders' deficit Advances to suppliers Amendment Flag Other comprehensive loss, net of tax of nil: Accounting Policies [Abstract] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss attributable to BeyondSpring Inc. Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,999,597 and 39,015,476 shares issued and outstanding as of December 31, 2022 and June 30, 2023, respectively) Ordinary shares, authorized (in shares) Ordinary shares, outstanding (in shares) Ordinary shares, issued (in shares) Deferred revenue Ordinary shares, par value (in dollars per share) Current Fiscal Year End Date Accrued expenses Document Fiscal Period Focus Document Fiscal Year Focus Accounts payable Document Period End Date Entity File Number Document Type us-gaap_PolicyTextBlockAbstract Accounting Policies Document Information [Line Items] Document Information [Table] Revenue Foreign exchange loss, net Basic and diluted (in shares) Entity Central Index Key Entity Registrant Name Current liabilities: Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] us-gaap_Assets Total assets Entity Address, City or Town Entity Address, Postal Zip Code Noncontrolling interests Basic and diluted (in dollars per share) Entity Address, State or Province Weighted-average shares outstanding Statement [Line Items] Income Statement [Abstract] Additional paid-in capital Short-term investments Shareholders' deficit Other income, net Restricted Cash Current assets: us-gaap_NetIncomeLoss Net loss attributable to BeyondSpring Inc. Contingently redeemable noncontrolling interests us-gaap_TableTextBlock Notes Tables Interest income us-gaap_Liabilities Total liabilities Less: Net loss attributable to noncontrolling interests Commitments and contingencies Mezzanine equity us-gaap_OperatingIncomeLoss Loss from operations Prepaid expenses and other current assets us-gaap_SellingGeneralAndAdministrativeExpense General and administrative us-gaap_LiabilitiesNoncurrent Total noncurrent liabilities Other noncurrent liabilities Less: Comprehensive loss attributable to noncontrolling interests Property and equipment, net us-gaap_PropertyPlantAndEquipmentNet us-gaap_LiabilitiesAndStockholdersEquity Total liabilities, mezzanine equity and shareholders' deficit Accumulated deficit us-gaap_ResearchAndDevelopmentExpense Research and development us-gaap_AssetsNoncurrent Total noncurrent assets Accumulated other comprehensive income us-gaap_InterestExpense Interest expenses Deferred revenue us-gaap_ContractWithCustomerLiabilityNoncurrent us-gaap_StockholdersEquity Total BeyondSpring Inc.’s shareholders’ deficit us-gaap_ProfitLoss Net loss us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Comprehensive loss us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Operating lease liabilities Class of Stock [Axis] Current portion of operating lease liabilities Operating lease right-of-use assets Net loss per share EX-101.PRE 6 bysi-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document And Entity Information
6 Months Ended
Jun. 30, 2023
Document Information [Line Items]  
Entity Central Index Key 0001677940
Entity Registrant Name BeyondSpring Inc.
Amendment Flag false
Current Fiscal Year End Date --12-31
Document Fiscal Period Focus Q2
Document Fiscal Year Focus 2023
Document Type 6-K
Entity File Number 001-38024
Entity Address, Address Line One 100 Campus Drive, West Side, 4th Floor, Suite 410
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
Document Period End Date Jun. 30, 2023
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 13,492 $ 34,396
Restricted Cash 9,736 0
Short-term investments 1,902 2,872
Advances to suppliers 444 492
Prepaid expenses and other current assets 217 763
Total current assets 25,791 38,523
Noncurrent assets:    
Property and equipment, net 1,800 1,868
Operating lease right-of-use assets 4,946 5,484
Other noncurrent assets 341 347
Total noncurrent assets 7,087 7,699
Total assets 32,878 46,222
Current liabilities:    
Accounts payable 1,501 1,081
Accrued expenses 1,682 2,470
Current portion of operating lease liabilities 784 966
Deferred revenue 1,751 1,351
Other current liabilities 1,104 1,484
Total current liabilities 6,822 7,352
Noncurrent liabilities:    
Operating lease liabilities 3,687 3,995
Deferred revenue 33,529 34,221
Other noncurrent liabilities 3,527 3,661
Total noncurrent liabilities 40,743 41,877
Total liabilities 47,565 49,229
Commitments and contingencies
Mezzanine equity    
Contingently redeemable noncontrolling interests 11,474 11,074
Shareholders' deficit    
Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,999,597 and 39,015,476 shares issued and outstanding as of December 31, 2022 and June 30, 2023, respectively) 4 4
Additional paid-in capital 368,679 368,857
Accumulated deficit (387,996) (375,276)
Accumulated other comprehensive income 1,223 436
Total BeyondSpring Inc.’s shareholders’ deficit (18,090) (5,979)
Noncontrolling interests (8,071) (8,102)
Total shareholders' deficit (26,161) (14,081)
Total liabilities, mezzanine equity and shareholders' deficit $ 32,878 $ 46,222
XML 9 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Ordinary shares, par value (in dollars per share) $ 0.0001 $ 0.0001
Ordinary shares, authorized (in shares) 500,000,000 500,000,000
Ordinary shares, issued (in shares) 39,015,476 38,999,597
Ordinary shares, outstanding (in shares) 39,015,476 38,999,597
XML 10 R4.htm IDEA: XBRL DOCUMENT v3.24.0.1
Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Revenue $ 875 $ 676
Operating expenses    
Research and development (9,214) (13,992)
General and administrative (5,145) (7,492)
Loss from operations (13,484) (20,808)
Foreign exchange loss, net (200) (350)
Interest income 281 41
Interest expenses 0 (17)
Other income, net 133 1,259
Loss before income tax (13,270) (19,875)
Income tax expenses (benefits) 9 (289)
Net loss (13,261) (20,164)
Less: Net loss attributable to noncontrolling interests (541) (1,675)
Net loss attributable to BeyondSpring Inc. $ (12,720) $ (18,489)
Net loss per share    
Basic and diluted (in dollars per share) $ (0.33) $ (0.47)
Weighted-average shares outstanding    
Basic and diluted (in shares) 38,976,761 39,065,710
Other comprehensive loss, net of tax of nil:    
Foreign currency translation adjustment $ 1,249 $ 949
Unrealized holding gain (loss) (5) 30
Comprehensive loss (12,017) (19,185)
Less: Comprehensive loss attributable to noncontrolling interests (84) (1,336)
Comprehensive loss attributable to BeyondSpring Inc. $ (11,933) $ (17,849)
EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 4 69 1 false 0 0 false 3 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 Sheet http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023 Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 Statements 2 false false R3.htm 002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals) Sheet http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 Sheet http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 Statements 4 false false All Reports Book All Reports bysi-20230630.xsd bysi-20230630_cal.xml bysi-20230630_def.xml bysi-20230630_lab.xml bysi-20230630_pre.xml bysi20230522_6k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 19 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bysi20230522_6k.htm": { "nsprefix": "bysi", "nsuri": "http://www.beyondspringpharma.com/20230630", "dts": { "schema": { "local": [ "bysi-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "bysi-20230630_cal.xml" ] }, "definitionLink": { "local": [ "bysi-20230630_def.xml" ] }, "labelLink": { "local": [ "bysi-20230630_lab.xml" ] }, "presentationLink": { "local": [ "bysi-20230630_pre.xml" ] }, "inline": { "local": [ "bysi20230522_6k.htm" ] } }, "keyStandard": 69, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 16, "http://fasb.org/us-gaap/2023": 10, "http://xbrl.sec.gov/dei/2023": 6 }, "contextCount": 4, "entityCount": 1, "segmentCount": 0, "elementCount": 87, "unitCount": 3, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 112, "http://xbrl.sec.gov/dei/2023": 13 }, "report": { "R1": { "role": "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023", "longName": "001 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-06-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals", "longName": "002 - Statement - Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals)", "shortName": "Audited Consolidated Balance Sheet as of December 31, 2022 and Unaudited Interim Condensed Consolidated Balance Sheet as of June 30, 2023 (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023", "longName": "003 - Statement - Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023", "shortName": "Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-01-01_2023-06-30", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bysi20230522_6k.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r6", "r272" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r42", "r71", "r191", "r208", "r209" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r37", "r272", "r291" ] }, "us-gaap_AdvancesOnInventoryPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdvancesOnInventoryPurchases", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Advances to suppliers", "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r279" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r53", "r70", "r87", "r109", "r117", "r121", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r154", "r158", "r169", "r188", "r235", "r272", "r276", "r285", "r286", "r288" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r66", "r72", "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r154", "r158", "r169", "r272", "r285", "r286", "r288" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsNoncurrent", "totalLabel": "Total noncurrent assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r154", "r158", "r169", "r285", "r286", "r288" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Noncurrent assets:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r68", "r266" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r11", "r30", "r189", "r222" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r36", "r223" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals" ], "lang": { "en-us": { "role": { "label": "Ordinary shares, outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r4", "r36", "r223", "r241", "r293", "r294" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Ordinary shares ($0.0001 par value; 500,000,000 shares authorized; 38,999,597 and 39,015,476 shares issued and outstanding as of December 31, 2022 and June 30, 2023, respectively)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r36", "r190", "r272" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss attributable to BeyondSpring Inc.", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r15", "r76", "r78", "r84", "r184", "r202" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss, net of tax of nil:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Less: Comprehensive loss attributable to noncontrolling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r25", "r28", "r76", "r78", "r83", "r183", "r201" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r28", "r51", "r76", "r78", "r82", "r182", "r200" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r140", "r141", "r144" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "us-gaap_ContractWithCustomerLiabilityNoncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r140", "r141", "r144" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Net loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r85", "r93", "r94", "r95", "r96", "r97", "r101", "r102", "r104", "r105", "r106", "r107", "r167", "r168", "r185", "r203", "r267" ] }, "us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicOtherDisclosuresAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares outstanding" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r277" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023", "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals", "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r277" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss, net", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r170", "r171", "r172", "r173", "r259" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss before income tax", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r43", "r58", "r109", "r116", "r120", "r122", "r186", "r196", "r269" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax expenses (benefits)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r61", "r62", "r99", "r100", "r114", "r149", "r152", "r204" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "negatedLabel": "Interest expenses", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r29", "r60", "r81", "r113", "r177", "r246", "r274", "r292" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r46", "r112" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023", "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals", "http://www.beyondspringpharma.com/20230630/role/statement-document-and-entity-information", "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r7", "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r155", "r158", "r159", "r169", "r221", "r268", "r276", "r285", "r288", "r289" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities, mezzanine equity and shareholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r41", "r55", "r194", "r272", "r283", "r284", "r287" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r9", "r67", "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r155", "r158", "r159", "r169", "r272", "r285", "r288", "r289" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesNoncurrent", "totalLabel": "Total noncurrent liabilities", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r5", "r32", "r33", "r34", "r35", "r87", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r155", "r158", "r159", "r169", "r285", "r288", "r289" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Noncurrent liabilities:" } } }, "auth_ref": [] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interests", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r12", "r54", "r87", "r127", "r130", "r132", "r133", "r134", "r137", "r138", "r169", "r193", "r225" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetIncomeLoss", "totalLabel": "Net loss attributable to BeyondSpring Inc.", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r44", "r48", "r59", "r65", "r75", "r77", "r80", "r87", "r91", "r93", "r94", "r95", "r96", "r99", "r100", "r103", "r109", "r116", "r120", "r122", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r168", "r169", "r199", "r243", "r260", "r261", "r269", "r274", "r285" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Less: Net loss attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r27", "r52", "r75", "r77", "r99", "r100", "r198", "r281" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r109", "r116", "r120", "r122", "r269" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r179" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r179" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r178" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r69" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Foreign currency translation adjustment", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r1" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Unrealized holding gain (loss)", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r73", "r74", "r126" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r8", "r272" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r10" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r47" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r280" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProfitLoss", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r65", "r75", "r77", "r86", "r87", "r91", "r99", "r100", "r109", "r116", "r120", "r122", "r127", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r153", "r156", "r157", "r168", "r169", "r186", "r197", "r213", "r243", "r260", "r261", "r269", "r270", "r271", "r275", "r281", "r285" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "verboseLabel": "Property and equipment, net", "label": "us-gaap_PropertyPlantAndEquipmentNet", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r3", "r187", "r195", "r272" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Contingently redeemable noncontrolling interests", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r19", "r20", "r21", "r22" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_ResearchAndDevelopmentExpense", "negatedLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r31", "r148", "r290" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r278", "r282" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r38", "r50", "r192", "r207", "r209", "r211", "r224", "r272" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r110", "r111", "r115", "r118", "r119", "r123", "r124", "r125", "r142", "r143", "r181" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_SellingGeneralAndAdministrativeExpense", "negatedLabel": "General and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r56", "r57", "r279" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023", "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals", "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r88", "r89", "r90", "r108", "r181", "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r237", "r238", "r239", "r240", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r262", "r273" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023", "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023-parentheticals", "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r88", "r89", "r90", "r108", "r181", "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r223", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r236", "r237", "r238", "r239", "r240", "r242", "r244", "r245", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r262", "r273" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total BeyondSpring Inc.\u2019s shareholders\u2019 deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r36", "r39", "r40", "r49", "r225", "r241", "r263", "r264", "r272", "r276", "r283", "r284", "r287", "r293" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Shareholders' deficit" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "totalLabel": "Total shareholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r23", "r24", "r26", "r63", "r64", "r79", "r88", "r89", "r90", "r92", "r98", "r128", "r129", "r139", "r145", "r146", "r147", "r150", "r151", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r174", "r175", "r176", "r180", "r205", "r206", "r212", "r225", "r241", "r263", "r264", "r265", "r275", "r283", "r284", "r287", "r293" ] }, "us-gaap_TemporaryEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityAbstract", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-audited-consolidated-balance-sheet-as-of-december-31-2022-and-unaudited-interim-condensed-consolidated-balance-sheet-as-of-june-30-2023" ], "lang": { "en-us": { "role": { "label": "Mezzanine equity" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesIssuedBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesIssuedBasic", "presentation": [ "http://www.beyondspringpharma.com/20230630/role/statement-unaudited-interim-condensed-consolidated-statements-of-comprehensive-loss-for-the-six-months-ended-june-30-2022-and-2023" ], "lang": { "en-us": { "role": { "label": "Basic and diluted (in shares)", "documentation": "This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic)." } } }, "auth_ref": [ "r17", "r18" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-13" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r268": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r269": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r270": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r271": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r272": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r273": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r275": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r276": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 20 0001171843-24-000560-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-24-000560-xbrl.zip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end XML 21 bysi20230522_6k_htm.xml IDEA: XBRL DOCUMENT 0001677940 2023-01-01 2023-06-30 0001677940 2022-12-31 0001677940 2023-06-30 0001677940 2022-01-01 2022-06-30 iso4217:USD iso4217:USD shares shares 0001677940 BeyondSpring Inc. false --12-31 Q2 2023 0.0001 0.0001 500000000 500000000 38999597 38999597 39015476 39015476 6-K 001-38024 100 Campus Drive, West Side, 4th Floor, Suite 410 Florham Park NJ 07932 2023-06-30 34396000 13492000 0 9736000 2872000 1902000 492000 444000 763000 217000 38523000 25791000 1868000 1800000 5484000 4946000 347000 341000 7699000 7087000 46222000 32878000 1081000 1501000 2470000 1682000 966000 784000 1351000 1751000 1484000 1104000 7352000 6822000 3995000 3687000 34221000 33529000 3661000 3527000 41877000 40743000 49229000 47565000 11074000 11474000 4000 4000 368857000 368679000 -375276000 -387996000 436000 1223000 -5979000 -18090000 -8102000 -8071000 -14081000 -26161000 46222000 32878000 676000 875000 13992000 9214000 7492000 5145000 -20808000 -13484000 -350000 -200000 41000 281000 17000 -0 1259000 133000 -19875000 -13270000 289000 -9000 -20164000 -13261000 -1675000 -541000 -18489000 -12720000 -0.47 -0.33 39065710 38976761 949000 1249000 30000 -5000 -19185000 -12017000 -1336000 -84000 -17849000 -11933000